134 related articles for article (PubMed ID: 12225814)
1. The effect of immunization with herpes simplex virus glycoprotein D fused with interleukin-2 against murine herpetic keratitis.
Inoue T; Inoue Y; Nakamura T; Yoshida A; Inoue Y; Tano Y; Shimomura Y; Fujisawa Y; Aono A; Hayashi K
Jpn J Ophthalmol; 2002; 46(4):370-76. PubMed ID: 12225814
[TBL] [Abstract][Full Text] [Related]
2. Preventive effect of local plasmid DNA vaccine encoding gD or gD-IL-2 on herpetic keratitis.
Inoue T; Inoue Y; Nakamura T; Yoshida A; Takahashi K; Inoue Y; Shimomura Y; Tano Y; Fujisawa Y; Aono A; Hayashi K
Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4209-15. PubMed ID: 11095617
[TBL] [Abstract][Full Text] [Related]
3. [The effect of immunization with herpes simplex virus glycoprotein D fused with interluekin-2 against murine herpetic keratitis].
Inoue T; Inoue Y; Nakamura T; Yoshida A; Inoue Y; Tano Y; Shimomura Y; Fujisawa Y; Aono A; Hayashi K
Nippon Ganka Gakkai Zasshi; 2001 Apr; 105(4):223-9. PubMed ID: 11329945
[TBL] [Abstract][Full Text] [Related]
4. Effect of herpes simplex virus-1 gD or gD-IL-2 DNA vaccine on herpetic keratitis.
Inoue T; Inoue Y; Hayashi K; Shimomura Y; Fujisawa Y; Aono A; Tano Y
Cornea; 2002 Oct; 21(7 Suppl):S79-85. PubMed ID: 12484704
[TBL] [Abstract][Full Text] [Related]
5. Topical administration of HSV gD-IL-2 DNA is highly protective against murine herpetic stromal keratitis.
Inoue T; Inoue Y; Hayashi K; Yoshida A; Nishida K; Shimomura Y; Fujisawa Y; Aono A; Tano Y
Cornea; 2002 Jan; 21(1):106-10. PubMed ID: 11805518
[TBL] [Abstract][Full Text] [Related]
6. Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis.
Hu K; He X; Yu F; Yuan X; Hu W; Liu C; Zhao F; Dou J
Immunol Invest; 2011; 40(3):265-78. PubMed ID: 21204603
[TBL] [Abstract][Full Text] [Related]
7. Coexpression of interleukin-2 enhances the immunization effect of a DNA vaccine expressing herpes simplex 1 glycoprotein D.
Li WR; Niu B; Wang JW; Feng ZJ; Wang DX
Acta Virol; 2006; 50(4):251-6. PubMed ID: 17177610
[TBL] [Abstract][Full Text] [Related]
8. An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice.
Hu K; Dou J; Yu F; He X; Yuan X; Wang Y; Liu C; Gu N
Vaccine; 2011 Feb; 29(7):1455-62. PubMed ID: 21185849
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulation by topical particle-mediated administration of cytokine plasmid DNA suppresses herpetic stromal keratitis without impairment of antiviral defense.
Bauer D; Lu M; Wasmuth S; Li H; Yang Y; Roggendorf M; Steuhl KP; Heiligenhaus A
Graefes Arch Clin Exp Ophthalmol; 2006 Feb; 244(2):216-25. PubMed ID: 16047184
[TBL] [Abstract][Full Text] [Related]
10. [Enhancement of herpes simplex virus-1 glycoprotein-D DNA vaccine induced specific immune responses by coimmunization with interleukin-2 genetic adjuvant].
Liu XJ; Zhu MZ; Song GX; Xu YF; Liu HW; Wang S; Yang BL; Dong FT; Xu XM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Feb; 27(1):67-72. PubMed ID: 15782496
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells.
Khan AA; Srivastava R; Chentoufi AA; Geertsema R; Thai NT; Dasgupta G; Osorio N; Kalantari M; Nesburn AB; Wechsler SL; BenMohamed L
J Virol; 2015 Jul; 89(13):6619-32. PubMed ID: 25878105
[TBL] [Abstract][Full Text] [Related]
12. Comparison of adjuvant efficacy of herpes simplex virus type 1 recombinant viruses expressing TH1 and TH2 cytokine genes.
Osorio Y; Ghiasi H
J Virol; 2003 May; 77(10):5774-83. PubMed ID: 12719570
[TBL] [Abstract][Full Text] [Related]
13. A crucial role for B and T lymphocyte attenuator in preventing the development of CD4+ T cell-mediated herpetic stromal keratitis.
Xia L; Zhang S; Zhou J; Li Y
Mol Vis; 2010 Oct; 16():2071-83. PubMed ID: 21042564
[TBL] [Abstract][Full Text] [Related]
14. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
Osorio Y; Ghiasi H
J Virol; 2005 Mar; 79(6):3297-308. PubMed ID: 15731224
[TBL] [Abstract][Full Text] [Related]
15. Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins.
Ghiasi H; Bahri S; Nesburn AB; Wechsler SL
Invest Ophthalmol Vis Sci; 1995 Jun; 36(7):1352-60. PubMed ID: 7775113
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of a DNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D in decreasing ocular disease severity following corneal HSV-1 challenge.
Frye TD; Chiou HC; Hull BE; Bigley NJ
Arch Virol; 2002 Sep; 147(9):1747-59. PubMed ID: 12209314
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
[TBL] [Abstract][Full Text] [Related]
18. Topical Administration Is a Promising Inoculating Route versus Intramuscular Inoculation for the Nanoparticle-Carried DNA Vaccine to Prevent Corneal Infections.
Hu K; Malla T; Zhai Y; Dong L; Tang R
Ophthalmic Res; 2015; 55(2):99-110. PubMed ID: 26650397
[TBL] [Abstract][Full Text] [Related]
19. The role of interleukin (IL)-2 and IL-4 in herpes simplex virus type 1 ocular replication and eye disease.
Ghiasi H; Cai S; Slanina SM; Perng GC; Nesburn AB; Wechsler SL
J Infect Dis; 1999 May; 179(5):1086-93. PubMed ID: 10191208
[TBL] [Abstract][Full Text] [Related]
20. A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity.
Royer DJ; Gurung HR; Jinkins JK; Geltz JJ; Wu JL; Halford WP; Carr DJJ
J Virol; 2016 Jun; 90(11):5514-5529. PubMed ID: 27030264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
